Search Result

Results for "

PET+tracer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Angiotensin Receptor (1) Apoptosis (2) Arrestin (1) Biochemical Assay Reagents (4) Calcium Channel (1) Carbonic Anhydrase (1) CCR (1) COX (1) CXCR (1) Cytochrome P450 (1) Dopamine Receptor (1) Drug Derivative (2) Drug Intermediate (2) FAAH (1) FAP (6) Fluorescent Dye (2) HDAC (1) hnRNP (1) iGluR (2) Integrin (1) mAChR (2) Methionine Adenosyltransferase (MAT) (1) mGluR (1) P-glycoprotein (1) Phosphodiesterase (PDE) (4) Potassium Channel (1) PSMA (3) Radionuclide-Drug Conjugates (RDCs) (6) Reference Standards (1) Sigma Receptor (1) Somatostatin Receptor (2) Synaptic Vesicle Proteins (1) Tau Protein (5) α-synuclein (1)
By Research Areas:	Cancer (18) Cardiovascular Disease (3) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (20)

By Targets:

Amyloid-β (1)

Angiotensin Receptor (1)

Apoptosis (2)

Arrestin (1)

Biochemical Assay Reagents (4)

Calcium Channel (1)

Carbonic Anhydrase (1)

CCR (1)

COX (1)

CXCR (1)

Cytochrome P450 (1)

Dopamine Receptor (1)

Drug Derivative (2)

Drug Intermediate (2)

FAAH (1)

FAP (6)

Fluorescent Dye (2)

HDAC (1)

hnRNP (1)

iGluR (2)

Integrin (1)

mAChR (2)

Methionine Adenosyltransferase (MAT) (1)

mGluR (1)

P-glycoprotein (1)

Phosphodiesterase (PDE) (4)

Potassium Channel (1)

PSMA (3)

Radionuclide-Drug Conjugates (RDCs) (6)

Reference Standards (1)

Sigma Receptor (1)

Somatostatin Receptor (2)

Synaptic Vesicle Proteins (1)

Tau Protein (5)

α-synuclein (1)

By Research Areas:

Cancer (18)

Cardiovascular Disease (3)

Inflammation/Immunology (5)

Metabolic Disease (3)

Neurological Disease (20)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-42110

Deschloroclozapine Maximum Cited Publications 83 Publications Verification	mAChR	Neurological Disease
Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist, with blood-brain barrier permeability. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with K_i of 6.3 and 4.2 nM, respectively. [ ¹¹C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging .

HY-125399

PSMA-11 1 Publications Verification HBED-CC-PSMA	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize ⁶⁸Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .

HY-42110A

Deschloroclozapine dihydrochloride Maximum Cited Publications 83 Publications Verification	mAChR	Neurological Disease
Deschloroclozapine dihydrochloride, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with K_i of 6.3 and 4.2 nM, respectively. [ ¹¹C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging .

HY-101184

T807 2 Publications Verification AV-1451	Tau Protein	Neurological Disease
T807 a novel tau positron emission tomography (PET) tracer.

HY-126192

Pittsburgh Compound B PiB; 6-OH-BTA-1	Amyloid-β	Neurological Disease
Pittsburgh Compound B (PiB) is a blood-brain barrier-permeable, specific Aβ deposition PET tracer that binds to Aβ(1-40) fibrils with a K_i value of 678.4 nM. Through click chemical modification (a clickable Pittsburgh Compound B derivative is prepared by introducing a PEG3 linker and an alkynyl group at the 6-hydroxy site of Pittsburgh Compound B, followed by covalent conjugation with azide-labeled fluorescent dyes or affinity tags via copper-catalyzed azide-alkyne cycloaddition (CuAAC)), Pittsburgh Compound B and its conjugates can be used for fluorescence imaging, ultrastructural studies, and enrichment and characterization of Aβ complexes. Pittsburgh Compound B is applicable to Alzheimer's disease research .

HY-175748

MK-7337	Radionuclide-Drug Conjugates (RDCs) α-synuclein	Neurological Disease
MK-7337 is an α-synuclein ligand with an affinity of < 1 nM. MK-7337 labeled with ¹¹C can be used as a PET tracer for neurodegenerative disorders like Parkinson’s disease imagination .

HY-101185

T808	Tau Protein	Neurological Disease
T808 is a selective tau protein-targeting ligand. T808 can be used to synthesize [ ¹⁸F]-T808, a highly selective tau protein positron emission tomography (PET) tracer. T808 can also be used to synthesize [ ³H]-T808, a marker for in vitro experiments. T808 can be used for the research of alzheimer’s disease .

HY-139048

Fluoroethylnormemantine	iGluR	Neurological Disease
Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ ¹⁸F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .

HY-179492

ACI-19278	hnRNP	Neurological Disease
ACI-19278 is a TDP-43 PET tracer with an average K_d of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [ ¹⁸F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions .

HY-173291

Tau ligand-1	Tau Protein	Neurological Disease
Tau ligand-1 (Compound 75) is a ligand for aggregated tau protein that can penetrate the blood-brain barrier . In tissues from patients with Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and Pick's disease, Tau ligand-1 exhibits high affinity for aggregated tau protein, with equilibrium dissociation constant (K_D) values ranging from 1 to 3.8 nM . Tau ligand-1 can serve as a potential positron emission tomography (PET) tracer and holds promise for application in positron emission tomography imaging studies of tau-related diseases in the central nervous system .

HY-W007746

1-Cyclohexeneboronic acid pinacol ester	Biochemical Assay Reagents	Others
1-Cyclohexeneboronic acid pinacol ester (Compound 4) is an organic borate that can be used in the synthesis of PET tracers .

HY-110141

ABP688	mGluR	Others
ABP688 is a high affinity human mGluR5 antagonist with anK_i of 1.7 nM. Radioisotope-labeled ABP688 can be used as a PET tracer for clinical imaging of the mGlu5 receptor .

HY-175229

PSMA ligand 1	PSMA	Cancer
PSMA ligand 1 (Compound 1c) is a PSMA ligand with an IC₅₀ of 26.74 nM. The [ ¹⁸F]-labeled PSMA ligand 1 can serve as a PSMA PET tracer and is used in research on the diagnosis of prostate cancer .

HY-128642

FAPI-2	FAP	Cancer
FAPI-2 is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as ⁶⁸Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose .

HY-163281

FSY-OSO2F	Fluorescent Dye	Cancer
FSY-OSO2F shows an uptake in MCF-7 cells through the regulation of L-Tyr, ASC, and ASC2 transporters. FSY-OSO2F can be used as a PET tracer, when labeled with ¹⁸F, and exhibits good uptake and good contrast in MCF-7 and 22Rv1 subcutaneous tumors .

HY-101184R

T807 (Standard) AV-1451 (Standard)	Reference Standards Tau Protein	Neurological Disease
T807 (Standard) is the analytical standard of T807. This product is intended for research and analytical applications. T807 a novel tau positron emission tomography (PET) tracer.

HY-158326

FAP-IN-4	FAP	Cancer
FAP-IN-4 (Comp 10) is a fibroblast activation protein (FAP) inhibitor and a ¹⁸F-labeled PET tracer targeting FAP. FAP-IN-4 can be used for cancer research .

HY-P11257

DOTA-BP1	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [ ⁶⁸Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma .

HY-175330

FAP-IN-6	FAP	Cancer
FAP-IN-6 (Compound 21) is a selectivity FAP inhibitor with an IC₅₀ of 13 pM. FAP-IN-6 has a high metabolic stability. FAP-IN-6 labeled with 18F can be used as a positron emission tomography (PET) tracer. FAP-IN-6 can be used for microenvironment of cancers research .

HY-128642A

FAPI-2 TFA	FAP	Cancer
FAPI-2 TFA is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as ⁶⁸Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 TFA has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose .

HY-Z15823

(R)-Verapamil Dexverapamil	Calcium Channel Potassium Channel Somatostatin Receptor Arrestin Apoptosis P-glycoprotein	Metabolic Disease Inflammation/Immunology
(R)-Verapamil (Dexverapamil) is an optically enantiomer of the oral-active Verapamil (HY-14275). (R)-Verapamil has a relatively low affinity for L-type calcium channels (Ca_v1.2) (IC₅₀ > 300 μM), and its IC₅₀ for sodium channels (sodium channel) is 3.19 μM. (R)-Verapamil exhibits SSTR2 agonistic activity, with an EC₅₀ of 1.3 μM. (R)-Verapamil significantly downregulates the expression of TXNIP protein in diabetic mouse models and significantly inhibits β-cell apoptosis (apoptosis), effectively controlling blood sugar. (R)-Verapamil can be used as a PET tracer for the function of P-glycoprotein (P-gp) .

HY-179227

HDAC6 ligand-7	HDAC	Neurological Disease
HDAC6 ligand-7 (Compound 16a) is a positron emission tomography (PET) tracer for the deacetylase 6 (HDAC6) enzyme with a K_d value of 1.66 nM. HDAC6 ligand-7 exhibits excellent HDAC6 inhibitory activity, with IC₅₀ values of 2.7 and 3.7 nM for hHDAC6 and mHDAC6, respectively, and has high selectivity for HDAC1/4/7/8. HDAC6 ligand-7 after being radioactively labeled with fluorine-18, [¹⁸F]HDAC6 ligand-7 shows varying degrees of radioactive uptake in PET, which can reflect the specific binding to HDAC6. HDAC6 ligand-7 can be used for the study of HDAC6 imaging .

HY-168343

Ga-DOTA-Olmutinib	Biochemical Assay Reagents	Cancer
Ga-DOTA-Olmutinib is a potential PET tracer designed to detect EGFR-positive cancers .

HY-159001

ZCDD083	Biochemical Assay Reagents	Others
ZCDD083 can be used as a positron emission tomography (PET) tracer for atherosclerotic plaques imagination, when labeled with ¹⁸F isotope .

HY-163075

SYB4	Sigma Receptor	Others
SYB4 (compound 5) is a PET tracer which suitable for imaging the Sigma-2 Receptor in the brain of nonhuman primates .

HY-158317

SFB-AMD3465	CXCR Biochemical Assay Reagents	Others
SFB-AMD3465 is an AMD3465 (HY-15971A) derivative. SFB-AMD3465 is utilized as positron emission tomography (PET) tracer for CXCR4, when labeled with radioactive Fluorine .

HY-139048A

Fluoroethylnormemantine hydrochloride	iGluR	Neurological Disease
Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ ¹⁸F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .

HY-177580

GP1 precursor	Integrin	Cardiovascular Disease
GP1 precursor has high affinity to GPIIb/IIIa receptors of activated platelets. GP1 precursor can be radiolabeled with [ ¹⁸F] and used as a PET Tracer for visualizing active platelet aggregation at the molecular level. GP1 precursor can be used for the detection of Thrombi .

HY-161965

MK-3168 (12C)	FAAH	Neurological Disease
MK-3168 (12C) is a FAAH inhibitor with IC₅₀ values of 1.0, 5.5, 1.7 nM for human, rhesus, rat, respectively. MK-3168 shows good brain uptake and FAAH-specific signal. ¹¹C MK-3168 can be used as FAAH PET tracer .

HY-172365

P7–2302	Phosphodiesterase (PDE)	Inflammation/Immunology
P7-2302 inhibits PDE7 and PDE4B with IC₅₀ of 0.18 nM and 77.3 nM. P7-2302 inhibits the efflux of P-gp and BCRP (breast cancer resistance protein), exhibits low uptake in rats brain. P7-2302 can be used as a PET tracer when labeled with 18F .

HY-165425

KR31173	Angiotensin Receptor	Cardiovascular Disease
KR31173 is an AT1 antagonist with an IC₅₀ of 3.27  nM. KR31173 can be used as a positron emission tomography (PET) tracer after being labeled with 11C isotope. KR31173 shows promising biodistribution and pharmacological properties in mice. KR31173 selectively binds to organs known to contain a high density of AT1 angiotensin receptors in CD-1 mice .

HY-169071S

ATX-1905	Phosphodiesterase (PDE)	Others
ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .

HY-162574

CYP11B2-IN-2	Cytochrome P450	Cancer
CYP11B2-IN-2 (Compound 10k) is an inhibitor for enzyme aldosterone synthase CYP11B2 with an IC₅₀ of 0.3 nM. CYP11B2-IN-2 CYP11B-IN-2 is labeled with 18F and can be used as a positron emission tomography (PET) tracer for the diagnosis of primary aldosteronism .

HY-180534

AldoView precursor-1	Drug Intermediate	Metabolic Disease
AldoView precursor-1 (Compound 7) is the key labeling precursor for the synthetic radioactive PET tracer [ ¹⁸F] AldoView. [ ¹⁸F] AldoView is a selective aldosterone synthase PET tracer used for imaging in primary hyperaldosteronism .

HY-181083

Tau ligand-2	Tau Protein	Neurological Disease
Tau ligand-2 is a tau aggregate ligand with a K_i value of 0.99 nM. Radiolabeled ( ¹⁸F) Tau ligand-2 serves as a PET tracer. Tau ligand-2 is applicable to research related to Alzheimer's disease .

HY-136873A

(Rac)-UCB-J	Synaptic Vesicle Proteins	Neurological Disease
(Rac)-UCB-J (Compound 23) is a ligand for synaptic vesicle protein 2A (SV2A), with a pIC₅₀ value of 8.2. (Rac)-UCB-J can be used as a PET tracer for SV2A to assist in the diagnosis of epilepsy research .

HY-181112

CAIX-IN-17	Carbonic Anhydrase	Cancer
CAIX-IN-17 is a carbonic anhydrase IX (CAIX) inhibitor with an IC₅₀ of 61 nM and accumulates specifically in CAIX-expressing xenograft tumors. CAIX-IN-17 can be labeled with ⁶⁸Ga and acts as a CAIX-targeted PET tracer for detection of clear-cell renal cell carcinoma .

HY-181580

FAP Ligand 3	FAP	Cancer
FAP Ligand 3 (compound 54) is a reagent that binds to FAP, with a K_i value of 0.092 nM against human targets. FAP Ligand 3 acts as a tumor-retaining agent and serves as a FAP-targeted positron emission tomography (PET) tracer for tumor imaging. FAP Ligand 3 is applicable to studies related to U87MG glioma .

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

HY-186094

(S,S)-Demethyl-reboxetine	Drug Derivative Drug Intermediate	Neurological Disease
(S,S)-Demethyl-reboxetine is a key phenolic precursor for the preparation of the PET tracer (S,S)-[ ¹¹C]-MeNER. (S,S)-Demethyl-reboxetine is also the demethylated derivative of Reboxetine (HY-14560). Efficient synthesis of the norepinephrine transporter (NET)-targeted tracer is achieved through ¹¹C methylation of (S,S)-Demethyl-reboxetine. (S,S)-Demethyl-reboxetine serves as a core raw material for the synthesis of radiopharmaceuticals related to NET imaging .

HY-181853

NOTA-SP2A-PSMAL	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
NOTA-SP₂A-PSMAL is a ligand targeting prostate-specific membrane antigen (PSMA), which competitively binds to PSMA with high binding affinity and an IC₅₀ value of 0.26 nM. ¹⁸F-labeled NOTA-SP₂A-PSMAL can be used as a PET tracer for positron emission tomography imaging of prostate cancer. NOTA-SP₂A-PSMAL can be used for the synthesis and research of radionuclide conjugates (RDCs) .

HY-P11553B

DOTA-ECL1i	Radionuclide-Drug Conjugates (RDCs) CCR	Cardiovascular Disease Inflammation/Immunology Cancer
DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with ⁶⁸Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer .

HY-D3174

PiF	Fluorescent Dye	Metabolic Disease Inflammation/Immunology
PiF is a fluorescent probe with high specificity for pancreatic β-cells (Ex/Em = 535 nm/565 nm), and its fluorescence signal increases significantly with elevated insulin concentrations in in vitro experiments. PiF enables visualization of rat and human islets transplanted via the portal vein in mouse livers with low liver background signals. The fluorine atom of PiF can be replaced by radioactive ¹⁸F to prepare a PET tracer. PiF can be used for research on type 1 diabetes .

HY-123446

JNJ-42259152	Phosphodiesterase (PDE)	Neurological Disease
JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases .

HY-181285

MAT2A ligand 1	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A ligand 1 is a MAT2A ligand inhibitor (IC₅₀₌29.5 nM) and *PET* tracer that crosses the blood-brain barrier. MAT2A ligand 1 enables non-invasive imaging of MAT2A-expressing tumors, with rapid tumor uptake equilibrium, a high tumor-to-muscle ratio, and specific tumor-binding properties. MAT2A ligand 1 is applicable to research related to non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, glioblastoma, pancreatic adenocarcinoma, urothelial carcinoma, breast cancer, and prostate cancer .

HY-180526

PDE2A-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE2A-IN-2 is a selective and brain-penetrant PDE2A inhibitor (K_i = 5.49 nM and 100 > fold selectivity over other PDE isoforms). The ¹¹C-labeled PDE2A-IN-2 serves as a positron emission tomography (PET) tracer for brain imaging in patients with neurodegenerative diseases. PDE2A-IN-2 educes the radiotracer signal in PDE2A-rich regions in vitro. PDE2A-IN-2 exhibits low binding affinity in vivo. PDE2A-IN-2 can be used for neurodegenerative diseases .

HY-183665

GBR-13119	Dopamine Receptor	Neurological Disease
GBR-13119 is a blood-brain barrier-permeable inhibitor of the presynaptic dopamine uptake system. GBR-13119 binds to dopamine uptake sites with high selectivity, without being affected by other neurotransmitter reuptake inhibitors. GBR-13119 exhibits a lipophilic systemic distribution profile with extremely low defluorination in rats, while it shows a differential characteristic of slow striatal washout in the brain of primates. GBR-13119 can serve as a PET tracer to achieve visualized imaging of the striatum in primates, and can reflect MPTP-induced dopaminergic neuron degeneration through reduced uptake. GBR-13119 can be widely applied to studies related to Parkinson's disease and dopaminergic neuron degeneration .

HY-160184

COX-1-IN-5	COX	Neurological Disease Inflammation/Immunology
COX-1-IN-5 (example 13, compound PS13) is a potent and selective COX-1 inhibitor (COX-1 IC₅₀ = 1 nM, COX-2 IC₅₀ > 0.1 μM) exhibiting >1000-fold selectivity over COX-2. COX-1-IN-5 possesses strong anti-inflammatory, antipyretic, analgesic, antithrombotic, anti-cancer activities. COX-1-IN-5 can be used for COX-mediated diseases research, such as inflammatory conditions and pain. COX-1-IN-5 radiolabeled with ¹¹C can be used as a selective PET tracer for whole‑body imaging of COX‑1 distribution and target engagement in vivo .

HY-181494

FAPI-X5	FAP	Cancer
FAPI-X5 is a fibroblast activation protein (FAP) inhibitor. FAPI-X5 binds to the FAP catalytic domain, forming hydrogen bonds with key active residues and engaging in π-π stacking to drive functional inhibition. FAPI-X5 exhibits albumin binding activity to prolong systemic circulation half-life. FAPI-X5 induces cytostatic effects on glioblastoma tumors, slowing tumor growth without regression. FAPI-X5, when labeled with ⁶⁸Ga, acts as a PET tracer with rapid tumor uptake and high-contrast imaging in glioblastoma tumor-bearing mice. FAPI-X5, when labeled with ¹⁷⁷Lu or ⁴⁷Sc, functions as a targeted radionuclide agent with prolonged tumor retention. FAPI-X5 can be used for the research of glioblastoma .

Cat. No.	상품명	Type

HY-D3174

PiF

Fluorescent Dyes

PiF is a fluorescent probe with high specificity for pancreatic β-cells (Ex/Em = 535 nm/565 nm), and its fluorescence signal increases significantly with elevated insulin concentrations in in vitro experiments. PiF enables visualization of rat and human islets transplanted via the portal vein in mouse livers with low liver background signals. The fluorine atom of PiF can be replaced by radioactive ¹⁸F to prepare a PET tracer. PiF can be used for research on type 1 diabetes .

Cat. No.	상품명	Target	Research Area

HY-P11257

DOTA-BP1	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [ ⁶⁸Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma .

HY-P11247

NOTA-SFCVHEM	Peptides	Cancer
NOTA-SFCVHEM can be activated by CTB. NOTA-SFCVHEM can be used to prepare PET tracer. NOTA-SFCVHEM has good stability, low toxicity, high tumor selectivity, and low liver accumulation .

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

HY-P11553B

DOTA-ECL1i	Radionuclide-Drug Conjugates (RDCs) CCR	Cardiovascular Disease Inflammation/Immunology Cancer
DOTA-ECL1i is a conjugate of the CCR2 inhibitor ECL1i (HY-P11553) and DOTA. When radiolabeled with ⁶⁸Ga, DOTA-ECL1i serves as a PET tracer that targets CCR2 expression. DOTA-ECL1i can be used in research related to pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer, and pancreatic cancer .

Cat. No.	상품명	Chemical Structure

HY-169071S

ATX-1905
ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: